Who Exports Amphotericin from India — 180 Suppliers Behind a $88.0M Market
India's amphotericin export market is supplied by 180 active exporters who collectively shipped $88.0M across 1,226 shipments. BHARAT SERUMS AND VACCINES LIMITED leads with a 36.8% market share, followed by SUN PHARMACEUTICAL INDUSTRIES LIMITED and EMCURE PHARMACEUTICALS LIMITED. The top 5 suppliers together control 90.8% of total export value, reflecting a concentrated market structure.
Top Amphotericin Exporters from India — Ranked by Export Value
BHARAT SERUMS AND VACCINES LIMITED is the leading amphotericin exporter from India, holding a 36.8% share of the $88.0M market across 1,226 shipments from 180 exporters. The top 5 suppliers — BHARAT SERUMS AND VACCINES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, EMCURE PHARMACEUTICALS LIMITED, JODAS EXPOIM PRIVATE LIMITED, POORNIMA HEALTHCARE — collectively control 90.8% of total export value, indicating a highly concentrated market. Individual shares are: BHARAT SERUMS AND VACCINES LIMITED (36.8%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (26.6%), EMCURE PHARMACEUTICALS LIMITED (23.5%), JODAS EXPOIM PRIVATE LIMITED (2.1%), POORNIMA HEALTHCARE (1.9%).
Top Amphotericin Exporters from India
Ranked by export value · 180 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | BHARAT SERUMS AND VACCINES LIMITED AMPHOLIP 50MG [AMPHOTERICIN B LIPID COMPAMPHOLIP 50MG [AMPHOTERICIN B LIPID COMPLEX]AMPHOLIP 100MG [AMPHOTERICIN B LIPID COMPLEX] | $32.4M | 47 | 36.8% |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LIMITED AMPHOLIP 50MG [AMPHOTERICIN B LIPID COMPLEX]AMPHOLIP 50MG [AMPHOTERICIN B LIPID COMPAMPHOTERICIN B LIPOSOME FOR INJECTION 50 | $23.4M | 6 | 26.6% |
| 3 | EMCURE PHARMACEUTICALS LIMITED AMPHOTERICIN B LIPOSOME FOR INJECTION,50MG/VIALMEDICINES AMPHOTERICIN B LIPOSOME FOR INJECTION,50MG/VIALAMPHOLIP 50MG [AMPHOTERICIN B LIPID COMPLEX] | $20.7M | 7 | 23.5% |
| 4 | JODAS EXPOIM PRIVATE LIMITED AMPHOLIP 100MG [AMPHOTERICIN B LIPID COMPLEX]AMPHOLIP 100MG AMPHOTERICIN B LIPID COMPLEXAMPHOLIP 50MG AMPHOTERICIN B LIPID COMPLEX | $1.8M | 1 | 2.1% |
| 5 | POORNIMA HEALTHCARE | $1.6M | 1 | 1.9% |
| 6 | CARITAS HEALTHCARE PRIVATE LIMITED | $1.3M | 1 | 1.4% |
| 7 | BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED MEDICINES AMPHOTERICIN B LIPOSOME FOR INJECTION,50MG/VIAL :MEDICINES AMPHOTERICIN B LIPOSOMALFOR INJ.50 MG :AMPHOTERICIN B LIPOSOMAL FOR INJ.50 MG | $1.2M | 4 | 1.4% |
| 8 | CIPLA LIMITED AMPHOLIP 50MG [AMPHOTERICIN B LIPID COMPLEX]AMPHOLIP 50MG [AMPHOTERICIN B LIPID COMP | $1.1M | 4 | 1.2% |
| 9 | GUFIC BIOSCIENCES LIMITED | $422.5K | 3 | 0.5% |
| 10 | LIFECARE INNOVATIONS PRIVATE LIMITED AMPHOTERICIN B LIPOSOME FOR INJECTION,50MG/VIALMEDICINES AMPHOTERICIN B LIPOSOME FOR INJECTION,50MG/VIALAMPHOTERICIN B LIPOSOME FORINJECTION,50MG/VIAL | $362.9K | 2 | 0.4% |
| 11 | UNITED BIOTECH PRIVATE LIMITED | $319.8K | 13 | 0.4% |
| 12 | CAPLIN POINT LABORATORIES LIMITED AMPHONEX 50MG [LIPOSOMAL AMPHOTERICIN B INJ. (LYOPHILIZED]#AMPHOLIP 50MG [AMPHOTERICIN B LIPID COMPLEX]AMPHOTERICIN B FOR INJECTION USP 50MG/VI | $315.8K | 4 | 0.4% |
| 13 | LYKA LABS LIMITED AMPHOLIP 50MG [AMPHOTERICIN B LIPID COMPAMPHOLIP 50MG AMPHOTERICIN B LIPID COMPLEX#AMPHOLIP 50MG [PACK SIZE : 10ML X 5MG] | $209.2K | 7 | 0.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Amphotericin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| BHARAT SERUMS AND VACCINES LIMITED | Not Listed | Yes, as of January 1 | No | Not verified | WHO-GMP certification valid as of January 17, 2005. |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Not Listed | Yes, as of December | No | Not verified | WHO-GMP certification valid as of December 1, 2022. |
| EMCURE PHARMACEUTICALS LIMITED | Not Listed | Yes, prequalified on | No | Not verified | WHO prequalified Molnupiravir 200mg capsules on December 26, 2022. |
| CIPLA LIMITED | Not Listed | Yes, as of February | No | Not verified | WHO-GMP certification valid as of February 2024. |
| GUFIC BIOSCIENCES LIMITED | Not Listed | Yes, as of December | No | Not verified | WHO-GMP certification valid as of December 1, 2022. |
| BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED | Not Listed | Yes, as of December | No | Not verified | WHO-GMP certification valid as of December 1, 2022. |
| LIFECARE INNOVATIONS PRIVATE LIMITED | Not Listed | Yes, as of December | No | Not verified | WHO-GMP certification valid as of December 1, 2022. |
| LYKA LABS LIMITED | Not Listed | Yes, as of December | No | Not verified | WHO-GMP certification valid as of December 1, 2022. |
TransData Nexus reviewed the regulatory standing of 8 leading Amphotericin exporters from India. 0 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 0 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Amphotericin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a central hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma. This concentration of expertise and infrastructure makes Hyderabad a key player in the manufacturing of APIs, which are essential components in the formulation of drugs like Amphotericin.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses companies such as Alembic Pharmaceuticals and Zydus Cadila. These firms specialize in the development and production of finished dosage forms, including Amphotericin formulations, leveraging the region's robust infrastructure and skilled workforce.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a significant export gateway for Indian pharmaceuticals. Mumbai, being the financial capital, provides access to international markets and regulatory bodies. Companies like Cipla, headquartered in Mumbai, utilize this strategic location to facilitate the export of pharmaceuticals, including Amphotericin, to various countries.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, has emerged as a major pharmaceutical manufacturing hub, partly due to favorable tax incentives. The region hosts over 1,000 pharmaceutical manufacturing units, making it one of the largest pharmaceutical hubs in Asia. Companies like Cipla and Dr. Reddy's Laboratories have established significant operations here, contributing to the production and distribution of various pharmaceuticals, including Amphotericin.
5Sourcing Recommendations
- Diversify Supplier Base: Given the high concentration of Amphotericin exports among a few suppliers, consider engaging with multiple manufacturers across different clusters to mitigate supply chain risks.
- Leverage Regional Specializations: Utilize Hyderabad for sourcing APIs, Ahmedabad-Vadodara for formulations, and Mumbai-Thane-Raigad for export logistics to optimize the supply chain.
- Monitor Regulatory Compliance: Ensure that suppliers adhere to international quality standards and regulatory requirements, especially when exporting to markets like the United States and the United Kingdom.
- Assess Infrastructure and Logistics: Evaluate the infrastructure and logistical capabilities of each cluster to ensure timely and efficient delivery of Amphotericin products.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can enhance its supply chain resilience and ensure a steady supply of Amphotericin to meet global demand.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Amphotericin exporters from India
Bharat Serums and Vaccines Limited — Mankind Pharma acquires 100% stake in BSV for ₹13,630 crore
Mankind Pharma Limited received all necessary regulatory approvals, including from the Competition Commission of India (CCI), to acquire a 100% stake in Bharat Serums and Vaccines Limited (BSV) for an enterprise value of approximately ₹13,630 crore.
Impact: This acquisition is expected to enhance Mankind Pharma's position in the biopharmaceutical sector, potentially influencing the Amphotericin export market.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
Sun Pharmaceutical Industries Limited announced the acquisition of Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology treatments, for $355 million.
Impact: While this acquisition primarily focuses on oncology, it may lead to expanded research and development capabilities that could indirectly affect Amphotericin production and exports.
Emcure Pharmaceuticals Limited — Emcure Pharmaceuticals launches IPO, lists on NSE and BSE
Emcure Pharmaceuticals Limited launched its initial public offering and listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in July 2024.
Impact: The IPO is expected to provide Emcure with additional capital for expansion, potentially enhancing its Amphotericin production and export capabilities.
Common Questions — Amphotericin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which amphotericin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, BHARAT SERUMS AND VACCINES LIMITED leads with 315 recorded shipments worth $32.4M. SUN PHARMACEUTICAL INDUSTRIES LIMITED (76 shipments) and EMCURE PHARMACEUTICALS LIMITED (89 shipments) are also established high-volume exporters.
Q How many amphotericin manufacturers are there in India?
India has 180 active amphotericin exporters with a combined export market of $88.0M across 1,226 shipments to 116 countries. The top 5 suppliers hold 90.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for amphotericin from India?
Average FOB unit price: $43.24 per unit, ranging from $0.00 to $1358.25. Average shipment value: $71.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 180 verified Indian exporters of Amphotericin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,226 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 116 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,226 Verified Shipments
180 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists